← Eichor
Condition: Advanced Lung Adenocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Lung Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
Phase N/A · 1 location(s) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Car · NCT07633626Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
NA · 7 location(s) · Institut Curie · NCT05475366Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followe
Phase 1/Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06440057Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 · 10 location(s) · Circle Pharma · NCT06577987A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06899789A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
Phase 1/Phase 2 · 1 location(s) · Shanghai Public Health Clinical Center · NCT03093688A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT04952272APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced
Phase 2 · 1 location(s) · West China Hospital · NCT06859684Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid
Phase 1 · 5 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07166601A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Met
Phase 1/Phase 2 · 3 location(s) · GI Innovation, Inc. · NCT07172802Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06126406A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent
Phase 1/Phase 2 · 8 location(s) · Bristol-Myers Squibb · NCT07223047A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793First in Human Study of SIM0610 in Solid Tumors
Phase 1 · 7 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT07348211A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06936735A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.